<DOC>
	<DOCNO>NCT01249027</DOCNO>
	<brief_summary>This prospective , observational , single-arm , open-label , multicenter , postapproval registry study China . The purpose study : - Evaluate continue safety effectiveness XIENCE V EECSS cohort real-world patient receive XIENCE V EECSS commercial use - Evaluate patient compliance dual antiplatelet therapy ( DAPT )</brief_summary>
	<brief_title>XIENCE V Everolimus Eluting Coronary Stent System ( EECSS ) China : Post-Approval , Single-Arm Study</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Coronary Occlusion</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>The patient patient 's legallyauthorized representative agrees participate study sign Ethics Committeeapproved inform consent form ( ICF ) . Only XIENCE V stent ( ) is/are implant coronary vasculature index procedure . The inability obtain signed ICF</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Drug elute stent</keyword>
	<keyword>Stents</keyword>
	<keyword>China</keyword>
	<keyword>DES</keyword>
	<keyword>XIENCE V EECSS</keyword>
</DOC>